PXD044170

PXD044170 is an original dataset announced via ProteomeXchange.

Title	Sacubitrilat reduces cardiomyocyte hypertrophy and proteasome activation in experimental mouse and human models
Description	Background: Angiotensin receptor–neprilysin inhibitors (ARNI) have been used in the treatment of heart failure (HF) for several years. Sacubitril/valsartan (Sac/Val) belongs to the group of ARNI and led to a reduction in mortality and pump failure. The mechanisms that mediate the beneficial effects of Sac/Val are not yet fully understood. In this study we investigated whether Sac/Val influences the two proteolytic systems, the ubiquitin-proteasome system (UPS) and the autophagy-lysosomal pathway (ALP), in a mouse model of pressure overload-induced HF and in a human cellular model of hypertrophy. Experimental approach: Transverse aortic constriction (TAC) or sham surgery was performed in 8-week old C57BL/6N mice. 14 days after TAC or sham surgery, the animals were randomized into the following 4 groups: 1) sham/vehicle, 2) sham/Sac/Val, 3) TAC/vehicle, and 4) TAC/Sac/Val. Sac/Val (57 mg/kg body weight/day) or vehicle (200 µl water) was given for further 6 weeks twice a day. Cardiac function was determined weekly by echocardiography. After 8 weeks, the hearts were taken and further investigated on molecular level. Human induced pluripotent stem cells were differentiated into cardiomyocytes (hiPSC-CMs) and treated with 100 nM endothelin 1 (ET1) and 40 µM Sac or 13 µM Val or both 40 µM Sac + 13 µM Val while using DMSO as a control. Analyses were performed on transcript and protein level as well as for UPS function. Key results: TAC mice showed a continuous decline in left ventricular function starting from day 14 after surgery. Sac/Val counteracted the deterioration especially of ejection fraction and cardiac output. The HF phenotype was further confirmed by an upregulation of the fetal gene program and of genes associated with fibrosis as well as a downregulation of genes involved in Ca2+ handling in TAC mice and was partially normalized by Sac/Val treatment. Evaluation of the ALP revealed no major impact of TAC or Sac/Val on the expression of ALP key marker. Investigation of the UPS showed a higher chymotrypsin-like activity after TAC, which was normalized by Sac/Val. In hiPSC-CMs, all treatments (Sac, Val, Sac/Val) normalized mean cell area. Sac but not Val prevented ET1-induced hypertrophic gene program and reduced the ET1-induced increase in UPS activity. Gross protein ubiquitination was only lowered in Sac/Val treated cells. The proteomic footprint showed a higher overlap between control, Sac and Sac/Val treated compared to the ET1 and Val groups. Both Sac-containing groups normalized sarcomeric protein levels, while Val mostly changed levels of proteins associated with energy metabolism. Conclusion: Sac/Val improved cardiac function and reduced fibrosis and hypertrophy. Whereas Sac/Val seems to exert its protective role independently of autophagy processes, the data obtained for the UPS suggest that Sac/Val has a beneficial effect on the UPS function. In the hiPSC-CMs, Sac proved to be the component of LCZ696 that mostly prevented the negative effects of ET1 on cell area, gene expression, proteome and UPS function.
HostingRepository	PRIDE
AnnounceDate	2025-05-06
AnnouncementXML	Submission_2025-05-06_10:08:27.875.xml
DigitalObjectIdentifier
ReviewLevel	Peer-reviewed dataset
DatasetOrigin	Original dataset
RepositorySupport	Unsupported dataset by repository
PrimarySubmitter	Bente Siebels
SpeciesList	scientific name: Homo sapiens (Human); NCBI TaxID: 9606;
ModificationList	iodoacetamide derivatized residue
Instrument	Orbitrap Fusion

Revision	Datetime	Status	ChangeLog Entry
0	2023-07-28 03:28:01	ID requested
⏵ 1	2025-05-06 10:08:28	announced

Meyer-Jens M, Wenzel K, Grube K, R, ü, debusch J, Kr, ä, mer E, Bahls M, M, ü, ller K, Vo, ß H, Schl, ü, ter H, Felix SB, Carrier L, K, ö, nemann S, Schlossarek S, Sacubitril/valsartan reduces proteasome activation and cardiomyocyte area in an experimental mouse model of hypertrophy. J Mol Cell Cardiol Plus, 7():100059(2024) [pubmed]

10.1016/j.jmccpl.2023.100059;

submitter keyword: sacubitril/valsartan, pressure overload, ubiquitin-proteasome system, heart failure,Autophagy-lysosomal pathway, cardiac function

Dr. Saskia Schlossarek
contact affiliation	Institute of Experimental Pharmacology and Toxicology, University Medical Center Hamburg-Eppendorf, Martinistr. 52, 20246 Hamburg, Germany
contact email	s.schlossarek@uke.de
lab head
Bente Siebels
contact affiliation	Section for Mass spectrometry and Proteomics, University Medical Center Hamburg-Eppendorf
contact email	b.siebels@uke.de
dataset submitter

Dataset FTP location NOTE: Most web browsers have now discontinued native support for FTP access within the browser window. But you can usually install another FTP app (we recommend FileZilla) and configure your browser to launch the external application when you click on this FTP link. Or otherwise, launch an app that supports FTP (like FileZilla) and use this address: ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2025/05/PXD044170

PRIDE project URI

• PRIDE
  1. PXD044170
     1. Label: PRIDE project
     2. Name: Sacubitrilat reduces cardiomyocyte hypertrophy and proteasome activation in experimental mouse and human models